Kymera Therapeutics Inc. (NASDAQ: KYMR) – Q3 2025 Earnings Outlook and Investor Relations Update
Kymera Therapeutics Inc. (NYSE: KYMR) is scheduled to release its third‑quarter 2025 earnings on November 4, 2025. Analysts and institutional investors are focusing on the company’s reported financial performance and future guidance, as well as its forthcoming participation in investor conferences.
Earnings Preview
- Projected Earnings Per Share (EPS): The consensus among 23 analysts estimates a positive EPS of $–0.763 for the quarter, representing a 6.95 % improvement over the previous year’s quarter, which yielded an EPS of $–0.820.
- Revenue Forecast: Consensus revenue expectations for Q3 2025 are $23.2 million, a 519.52 % increase from the $3.7 million recorded in the comparable period last year.
These figures suggest significant growth in top‑line activity, although the company is still operating at a loss per share.
Institutional Coverage
- Guggenheim Capital Management has assigned a Buy rating to KYMR and set a $90 target price. The firm’s coverage announcement was reported by multiple news feeds, including Investing.com and feeds.feedburner.com.
- The Buy rating reflects confidence in Kymera’s pipeline of oral small‑molecule degraders and its strategic positioning in the immunology therapeutic space.
Investor Conference Participation
Kymera will engage in fireside chats and other investor events during the November conference season. The company confirmed its participation in meetings hosted by Guggenheim, providing an opportunity for shareholders and potential investors to discuss upcoming clinical milestones and financial strategy directly with management.
Market Context
- Current Share Price (02 Nov 2025): $59.72
- 52‑Week High: $63.96 (15 Oct 2025)
- 52‑Week Low: $19.45 (08 Apr 2025)
- Market Capitalization: $4.42 billion
- Price‑to‑Earnings Ratio: –17.78
The company’s valuation remains negative on an earnings basis, reflecting its ongoing investment in research and development. However, the sharp rise in revenue and the positive EPS trajectory are highlighted as potential turning points in the company’s financial outlook.
Key Takeaways
- Kymera’s Q3 2025 earnings are expected to show a marked improvement in revenue and a modest EPS turnaround.
- Guggenheim’s Buy rating and $90 price target underscore institutional optimism about the company’s pipeline and market strategy.
- Upcoming investor conferences will serve as platforms for the company to elaborate on clinical developments and financial guidance.
Investors should monitor the November 4 earnings release and subsequent conference proceedings for updated guidance and strategic direction.
